AKBA has been the subject of a number of other reports. ValuEngine upgraded Akebia Therapeutics from a sell rating to a hold rating in a report on Thursday, August 1st. Zacks Investment Research upgraded Akebia Therapeutics from a sell rating to a hold rating in a report on Friday, July 12th. HC Wainwright reiterated a buy rating and issued a $17.00 price target on shares of Akebia Therapeutics in a report on Monday. Finally, Mizuho set a $16.00 price target on Akebia Therapeutics and gave the company a buy rating in a report on Friday, August 9th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $12.45.
Akebia Therapeutics stock traded down $0.16 during midday trading on Thursday, hitting $5.10. 1,183,232 shares of the company were exchanged, compared to its average volume of 1,086,859. The company’s fifty day moving average price is $4.21 and its 200-day moving average price is $5.54. Akebia Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $10.45. The company has a market cap of $602.62 million, a PE ratio of -2.09 and a beta of 1.43. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.70 and a quick ratio of 1.05.
Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its stake in Akebia Therapeutics by 290.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 18,674 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 13,896 shares during the last quarter. Boston Partners grew its stake in Akebia Therapeutics by 1.3% during the 1st quarter. Boston Partners now owns 283,044 shares of the biopharmaceutical company’s stock worth $2,318,000 after buying an additional 3,666 shares during the last quarter. IndexIQ Advisors LLC bought a new position in Akebia Therapeutics during the 1st quarter worth $1,522,000. DekaBank Deutsche Girozentrale grew its stake in Akebia Therapeutics by 20.5% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,500 shares during the last quarter. Finally, Lido Advisors LLC grew its stake in Akebia Therapeutics by 26.5% during the 1st quarter. Lido Advisors LLC now owns 47,686 shares of the biopharmaceutical company’s stock worth $390,000 after buying an additional 9,986 shares during the last quarter. Institutional investors and hedge funds own 71.88% of the company’s stock.
About Akebia Therapeutics
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.